Leonard L. Mazur - 08 Aug 2025 Form 4 Insider Report for Citius Pharmaceuticals, Inc. (CTXR)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: CTXR
Reported as of: 08 Aug 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 23 Sep 2025, 16:05:24 UTC
Prior SEC filing: 16 Dec 2024
Next SEC filing: 01 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ Alexander M. Donaldson, by power of attorney

Key filing fact

Leonard L. Mazur filed Form 4 for Citius Pharmaceuticals, Inc. (CTXR) on 23 Sep 2025.

Key facts

This page summarizes Leonard L. Mazur's Form 4 filing for Citius Pharmaceuticals, Inc. (CTXR).
4 reported transactions and 13 derivative rows are listed below.
Accepted by SEC: 23 Sep 2025, 16:05.

Change

Previous filing in this sequence was filed on 16 Dec 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001463414 Primary reporting owner

Mazur Leonard L

Relationship: Chief Executive Officer, Director
Address: C/O CITIUS PHARMACEUTICALS, INC., 11 COMMERCE DRIVE, 1ST FLOOR, CRANFORD
Signature: /s/ Alexander M. Donaldson, by power of attorney
Signature date: 23 Sep 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CTXR holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 410,214
Date: 08 Aug 2025
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CTXR transaction Derivative

Warrant to Purchase Common Stock

Disposed to Issuer

Transaction value
Shares: -125,490
Change %: -100%
Price
Shares after: 0
Date: 08 Aug 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 125,490
Exercise price: $28.75
Footnotes: F1

CTXR transaction Derivative

Warrant to Purchase Common Stock

Award

Transaction value
Shares: +125,490
Change %
Price
Shares after: 125,490
Date: 08 Aug 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 125,490
Exercise price: $28.75
Footnotes: F1

CTXR transaction Derivative

Warrant to Purchase Common Stock

Disposed to Issuer

Transaction value
Shares: -89,388
Change %: -100%
Price
Shares after: 0
Date: 08 Aug 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 89,388
Exercise price: $19.25
Footnotes: F2

CTXR transaction Derivative

Warrant to Purchase Common Stock

Award

Transaction value
Shares: +89,388
Change %
Price
Shares after: 89,388
Date: 08 Aug 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 89,388
Exercise price: $19.25
Footnotes: F2

CTXR holding Derivative

Stock Option (Right to Purchase Common Stock)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 24,000
Date: 08 Aug 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 24,000
Exercise price: $9.50
Footnotes: F3

CTXR holding Derivative

Stock Option (Right to Purchase Common Stock)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 22,000
Date: 08 Aug 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 22,000
Exercise price: $17.50
Footnotes: F4

CTXR holding Derivative

Stock Option (Right to Purchase Common Stock)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 22,000
Date: 08 Aug 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 22,000
Exercise price: $31.25
Footnotes: F5

CTXR holding Derivative

Stock Option (Right to Purchase Common Stock)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 26,000
Date: 08 Aug 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 26,000
Exercise price: $51.00
Footnotes: F6

CTXR holding Derivative

Stock Option (Right to Purchase Common Stock)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 12,000
Date: 08 Aug 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 12,000
Exercise price: $50.00
Footnotes: F6

CTXR holding Derivative

Stock Option (Right to Purchase Common Stock)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 8,000
Date: 08 Aug 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 8,000
Exercise price: $25.25
Footnotes: F6

CTXR holding Derivative

Stock Option (Right to Purchase Common Stock)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 7,000
Date: 08 Aug 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 7,000
Exercise price: $16.75
Footnotes: F6

CTXR holding Derivative

Stock Option (Right to Purchase Common Stock)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 6,000
Date: 08 Aug 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 6,000
Exercise price: $40.50
Footnotes: F6

CTXR holding Derivative

Stock Option (Right to Purchase Common Stock)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 1,600
Date: 08 Aug 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,600
Exercise price: $86.25
Footnotes: F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 6 footnotes

Footnote F1

The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from August 14, 2025 to August 14, 2026, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on August 13, 2018 and was exercisable immediately.

Footnote F2

The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from September 27, 2025 to September 27, 2026, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on September 27, 2019 and was exercisable immediately.

Footnote F3

The options were granted on November 7, 2024. The options vest 1/3 on each of the one-year, two-year and three-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of each such vesting date.

Footnote F4

The options were granted on October 10, 2023. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of each such vesting date.

Footnote F5

The options were granted on October 4, 2022. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of each such vesting date.

Footnote F6

The options are vested in full and exercisable immediately.

SEC remarks

All share amounts reflect the 1-for-25 reverse stock split effective November 22, 2024.